CureVac (NASDAQ:CVAC) Shares Down 4.8%

Shares of CureVac (NASDAQ:CVACGet Free Report) traded down 4.8% during trading on Friday . The company traded as low as $4.67 and last traded at $4.75. 115,327 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 997,280 shares. The stock had previously closed at $4.99.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CVAC. Guggenheim reissued a “neutral” rating on shares of CureVac in a research note on Friday, April 5th. Leerink Partnrs downgraded CureVac from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 25th. Finally, SVB Leerink downgraded CureVac from an “outperform” rating to a “market perform” rating and lowered their target price for the stock from $12.00 to $4.00 in a research note on Thursday, April 25th.

Get Our Latest Stock Report on CureVac

CureVac Price Performance

The stock has a market cap of $1.01 billion, a P/E ratio of -3.38 and a beta of 2.68. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.09 and a current ratio of 2.25. The business has a 50 day simple moving average of $3.17 and a 200-day simple moving average of $3.70.

CureVac (NASDAQ:CVACGet Free Report) last posted its quarterly earnings results on Thursday, May 23rd. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.12). The firm had revenue of $13.43 million for the quarter, compared to the consensus estimate of $14.51 million. CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. On average, sell-side analysts forecast that CureVac will post -1.11 EPS for the current year.

Institutional Trading of CureVac

Large investors have recently modified their holdings of the business. Swiss National Bank lifted its position in CureVac by 1.8% in the 3rd quarter. Swiss National Bank now owns 221,406 shares of the company’s stock worth $1,462,000 after buying an additional 3,925 shares during the last quarter. Pathstone Family Office LLC bought a new stake in CureVac in the third quarter valued at approximately $89,000. Deutsche Bank AG lifted its position in CureVac by 5.1% in the third quarter. Deutsche Bank AG now owns 72,510 shares of the company’s stock valued at $495,000 after purchasing an additional 3,491 shares during the last quarter. Federated Hermes Inc. lifted its position in CureVac by 33.3% in the third quarter. Federated Hermes Inc. now owns 40,000 shares of the company’s stock valued at $273,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Optiver Holding B.V. lifted its position in CureVac by 2,407.0% in the third quarter. Optiver Holding B.V. now owns 6,844 shares of the company’s stock valued at $47,000 after purchasing an additional 6,571 shares during the last quarter. Institutional investors own 17.26% of the company’s stock.

CureVac Company Profile

(Get Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

Read More

Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.